Please login to the form below

cladribine

This page shows the latest cladribine news and features for those working in and with pharma, biotech and healthcare.

MS and cholesterol drugs picked for new UK rapid uptake push

Merck’s Mavenclad (cladribine) for treating highly active relapsing-remitting multiple sclerosis in adults - A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment

Latest news

Sanofi licences Principia MS drug in $805m deal

The three established players in the oral MS therapy category are also about to see additional competition from new entrant Merck KGaA, which bagged EU approval for Mavenclad (cladribine) in August.
Merck mulls sale of consumer health division

The news comes a few days after Merck picked up an important new approval for its pharma division in Europe, with the EMA clearing Mavenclad (cladribine) for the treatment of
Merck gets CHMP backing for long-delayed oral MS drug

Cladribine, which will be branded as Mavenclad, was originally rejected by the committee in 2010. ... The company thinks oral cladribine has a key differentiator from its rivals, which require daily dosing.
Avelumab costs peg back profit at Merck KGaA

Avelumab and other pipeline candidates such as oral MS therapy cladribine have assumed even more importance for Merck since it abandoned plans to seek approval of evofosfamide in advanced soft tissue
Merck's pharma unit faces tougher 2017 as fertility boost recedes

Top of that list is oral MS therapy cladribine, which was submitted for approval in the EU in June, and according to Kuhnert is proceeding through regulatory review as expected.

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest appointments

XenoPort appoints chief medical officer

Prior to joining Biogen Idec Dr Kim was with Merck Serono, serving as medical director for the phase III programme of cladribine, which failed to impress in MS.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Account Director, Medical Education: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Senior Medical Writer: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Director – Healthcare PR: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Editor – Medical Education Agency – Bucks: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...